"Pursuant to the Amendment all minimum R&D requirements and all milestone payments due to ACT under the Exclusive License Agreement have been eliminated. The Company will no longer pay any royalties under the ACT IP Agreement and Infigen IP Agreement, and its obligation to pay royalties that ranged from 6%-12% under the UMass IP Agreement has been reduced to 0.25% of the net sales of products using technology covered by the UMass IP Agreement. "
We needed their business then and now. Imagine if they say they are using better or equal SC from another co. for their creams. ISCO was hoping to cash in on the ACTC fame/association they're waiting for successful results too-or they're gonna have to change their formula.